It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Synaptic loss, neuronal death, and circuit remodeling are common features of central nervous system neurodegenerative disorders. Retinitis pigmentosa (RP), the leading cause of inherited blindness, is a group of retinal dystrophies characterized by photoreceptor dysfunction and death. The insulin receptor, a key controller of metabolism, also regulates neuronal survival and synaptic formation, maintenance, and activity. Indeed, deficient insulin receptor signaling has been implicated in several brain neurodegenerative pathologies. We present evidence linking impaired insulin receptor signaling with RP. We describe a selective decrease in the levels of the insulin receptor and its downstream effector phospho-S6 in retinal horizontal cell terminals in the rd10 mouse model of RP, as well as aberrant synapses between rod photoreceptors and the postsynaptic terminals of horizontal and bipolar cells. A gene therapy strategy to induce sustained proinsulin, the insulin precursor, production restored retinal insulin receptor signaling, by increasing S6 phosphorylation, without peripheral metabolic consequences. Moreover, proinsulin preserved photoreceptor synaptic connectivity and prolonged visual function in electroretinogram and optomotor tests. These findings point to a disease-modifying role of insulin receptor and support the therapeutic potential of proinsulin in retinitis pigmentosa.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Centro de Investigaciones Biológicas Margarita Salas (CSIC), Department of Molecular Biomedicine, Madrid, Spain (GRID:grid.418281.6) (ISNI:0000 0004 1794 0752); Universidad Complutense de Madrid, Ciudad Universitaria, Neurovascular Research Unit, Department of Pharmacology and Toxicology and Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); Instituto de Investigación Hospital 12 de Octubre (IMAS12), Madrid, Spain (GRID:grid.512044.6) (ISNI:0000 0004 7666 5367)
2 Centro de Investigaciones Biológicas Margarita Salas (CSIC), Department of Molecular Biomedicine, Madrid, Spain (GRID:grid.418281.6) (ISNI:0000 0004 1794 0752)
3 University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL), Institute of Neurosciences of Castilla y León (INCYL), Cell Biology and Pathology Department, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)
4 Universidad Complutense de Madrid, Ciudad Universitaria, Neurovascular Research Unit, Department of Pharmacology and Toxicology and Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); Instituto de Investigación Hospital 12 de Octubre (IMAS12), Madrid, Spain (GRID:grid.512044.6) (ISNI:0000 0004 7666 5367)
5 School of Veterinary Medicine, Universitat Autònoma de Barcelona, Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, Bellaterra, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
6 Facultad de Medicina, Universidad de Alcalá, Department of System Biology, Alcalá de Henares, Spain (GRID:grid.7159.a) (ISNI:0000 0004 1937 0239); Instituto Ramón y Cajal de Investigación Sanitaria, ISCIII, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
7 Centro de Investigaciones Biológicas Margarita Salas (CSIC), Department of Molecular Biomedicine, Madrid, Spain (GRID:grid.418281.6) (ISNI:0000 0004 1794 0752); Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)